Nile Red

Nile Red

SCHEMBL29373685

CCN(CC)c1ccc2nc3c4ccccc4c(=O)cc-3oc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
NPC1 O15118 2/20 1.00
POLB P06746 2/20 1.00
RAB9A P51151 2/20 1.00
SCP2 P22307 1/20 0.62
GPR84 Q9NQS5 10/20 0.47
PTPRA P18433 1/20 0.46
PTPRB P23467 1/20 0.46
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
GLA P06280 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 3/20 0.43
CASP1 P29466 3/20 0.43
CASP7 P55210 3/20 0.43
BRCA1 P38398 3/20 0.43
TP53 P04637 2/20 0.43
HTT P42858 2/20 0.43
HSD17B10 Q99714 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nile Red SCHEMBL49047 1.00 MEN1 (1.00) MEN1KMT2ANPC1POLBRAB9A
Nile Red SCHEMBL28703996 0.97 MEN1 (0.93) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL7815341 0.89 MEN1 (0.79) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL23266942 0.88 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL15398206 0.88 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL15398222 0.88 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
Nile Blue SCHEMBL12393690 0.87 MEN1 (0.77) MEN1KMT2ANPC1POLBRAB9A
Nile Blue SCHEMBL29356294 0.87 MEN1 (0.77) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL8858355 0.86 NPC1 (0.76) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL56792 0.86 MEN1 (0.76) MEN1KMT2ANPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616656-B2 Adventitial painting modality of local drug delivery to abate intimal hyperplasia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-05-05 US claimed
EP-3929585-B1 A METHOD AND A BIOSENSING DEVICE FOR PEPTIDES AND PROTEINS DETECTION AND QUANTIFICATION INST SUPERIOR DE ENGENHARIA DO PORTO (PT) 2024-12-25 EP claimed
US-20240238198-A1 AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2024-07-18 US claimed
EP-3740585-B1 IMPROVING DETECTION OF MICROORGANISMS BACTOBYTE LTD (IL) 2023-09-27 EP claimed
CN-116274188-A Device for purging UHP device and purging method thereof 镇江微笙科技有限公司 2023-06-23 CN claimed
WO-2022246462-A1 AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-11-24 WO claimed
US-20260144740-A1 COSMETIC ACTIVE INGREDIENT DERIVED FROM A NON-VOLATILE FRACTION OF CANARIUM EXUDATE AND USES THEREOF FLORE SCOLA (FR) 2026-05-28 US disclosed
CN-122037594-A Polymethyl methacrylate nanoparticle compounded Pickering emulsified asphalt and preparation method thereof 太原理工大学 2026-05-15 CN disclosed
US-20260126387-A1 IN-SITU DETECTION METHOD FOR REACTIVE OXYGEN SPECIES BASED ON RATIOMETRIC FLUORESCENT PROBE NANJING UNIVERSITY (CN) 2026-05-07 US disclosed
US-12616656-B2 Adventitial painting modality of local drug delivery to abate intimal hyperplasia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-05-05 US disclosed
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 US disclosed
US-20260108503-A1 POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441 UNIV DE GENE DE GENEVE (CH) 2026-04-23 US disclosed
US-12594310-B2 Composition comprising lactic acid bacteria derived from green tea for improving liver function AMOREPACIFIC CORPORATION (KR) 2026-04-07 US disclosed
US-11324823-B2 Biophotonic materials and uses thereof KLOX TECHNOLOGIES INC. (CA) 2022-05-10 US disclosed
WO-2022092338-A1 METHOD FOR INCREASING METABOLIC PRODUCTIVITY OF MICROORGANISMS USING C1 GAS BY USING ORGANIC MATERIAL-BASED NANOFLUID 충남대학교산학협력단 2022-05-05 WO disclosed
WO-2022091822-A1 METHOD FOR FREEZING CELL STRUCTURE 国立大学法人大阪大学 2022-05-05 WO disclosed
WO-2022055929-A1 POLYVALENT STING ACTIVATING COMPOSITIONS AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-03-17 WO disclosed
US-20220071903-A1 POLYVALENT STING ACTIVATING COMPOSITIONS AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-03-10 US disclosed
EP-3964511-A1 BIOORTHOGONAL CHOLESTEROL PROBE AND USES THEREOF Universidad del País Vasco/Euskal Herriko Unibertsitatea (ES) 2022-03-09 EP disclosed
US-20220031849-A1 NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12594310-B2 Composition comprising lactic acid bacteria derived from green tea for improving liver function LIPC, FABP1, FABP2 MEN1 4879/4885KMT2A 3805/4885NPC1 3222/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 MEN1 4640/4885KMT2A 2591/4885NPC1 154/4885
US-20220071903-A1 POLYVALENT STING ACTIVATING COMPOSITIONS AND USES THEREOF STING1, CGAS, TLR7 MEN1 539/4885KMT2A 3087/4885NPC1 2734/4885
US-20260108503-A1 POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441 SHH, SMO, GLI1 MEN1 3189/4885KMT2A 1375/4885NPC1 2789/4885
US-20220031849-A1 NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES GPR88, GPR65, ARRB1 MEN1 3215/4885KMT2A 3428/4885NPC1 109/4885
US-20260144740-A1 COSMETIC ACTIVE INGREDIENT DERIVED FROM A NON-VOLATILE FRACTION OF CANARIUM EXUDATE AND USES THEREOF NOTUM, CUTA, ALOX15 MEN1 3961/4885KMT2A 4741/4885NPC1 434/4885
US-20260126387-A1 IN-SITU DETECTION METHOD FOR REACTIVE OXYGEN SPECIES BASED ON RATIOMETRIC FLUORESCENT PROBE CYBA, NOX4, IK MEN1 4803/4885KMT2A 4636/4885NPC1 749/4885
US-12616656-B2 Adventitial painting modality of local drug delivery to abate intimal hyperplasia ADRA1B, ADRB1, ADRB3 MEN1 4609/4885KMT2A 3337/4885NPC1 2389/4885
US-20240238198-A1 AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIA SHMT1, PNISR, CD44 MEN1 3600/4885KMT2A 1632/4885NPC1 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.